Shoko Saito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Shoko Saito has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Mitsuru Okuwaki
Laboratory of Biochemistry, Graduate School of Pharmaceutical Sciences, Kitasato University, 5-9-1 Shirokane, Minato-Ku, Tokyo, 108-8641, Japan; School of Pharmacy, Kitasato University, 5-9-1 Shirokane, Minato-Ku, Tokyo, 108-8641, Japan
2 shared publications Akemi Araki
Department of Immunology, Yamagata University, Faculty of Medicine, Japan
1 shared publication- Akira Midorikawa
Chuo University
1 shared publication Asami Suda
Pharmaceutical Engineering, School of Pharmacy, Aichi Gakuin University, Nagoya, Japan
1 shared publication- Chisato Takahashi
Fine Structure Characterization Reseach Group, Research Institute of Core Technology for Materials Innovation, Department of Materials and Chemistry, National Institute of Advanced Industrial Science and Technology (AIST)
1 shared publication Daiki Nishikata
Laboratory of Biochemistry School of Pharmacy Kitasato University Minato‐ku Japan
1 shared publication
Latest Publications
- 2 May 2025
- Published by Wiley in The FEBS Journal
The oncoprotein DEK controls growth‐regulated gene expression by enhancing the DNA‐binding activity of basic leucine zipper transcription factors
Overexpression of the oncogenic protein DEK is associated with a poor prognosis in various cancers. However, the molecular mechanisms by which DEK promotes cancer development and malignant transformation remain unclear. Previous studies have shown that DEK interacts with transcription factors, such as AP‐2a and C/EBPα, and enhances their transcriptional activity. We hypothesized that DEK promotes cancer cell phenotypes by regulating transcription factors. We analyzed the interaction between DEK and the transcription factors to evaluate this hypothesis. We found that DEK binds to the basic regions within the basic leucine zipper (bZIP)‐ and basic helix–loop–helix leucine zipper (bHLH‐ZIP)‐ transcription factors. Interestingly, DEK enhanced the DNA‐binding capacity of two bZIP transcription factors, C/EBPα and ATF3, in vitro without being a component of the transcription factor‐DNA complex. We performed DEK knockdown in lung adenocarcinoma A549 cells and examined the global transcriptome changes to determine the biological significance of the interaction between DEK and transcription factors. We found that diverse genes regulating cell growth and amino acid metabolism, which may potentially be regulated by c‐Jun, a subunit of the bZIP transcription factor AP1, and c‐Myc, a bHLH‐ZIP transcription factor, were decreased by DEK knockdown. Consistent with these transcriptome changes, the cell growth, colony formation, and cell migration abilities of A549 cells were decreased by DEK knockdown. These results suggest that DEK promotes cancer cell malignancy by regulating the functions of the bZIP and bHLH‐ZIP transcription factors.
- 2 May 2025
- Published by Wiley in The FEBS Journal
The oncoprotein DEK controls growth‐regulated gene expression by enhancing the DNA‐binding activity of basic leucine zipper transcription factors
Overexpression of the oncogenic protein DEK is associated with a poor prognosis in various cancers. However, the molecular mechanisms by which DEK promotes cancer development and malignant transformation remain unclear. Previous studies have shown that DEK interacts with transcription factors, such as AP‐2a and C/EBPα, and enhances their transcriptional activity. We hypothesized that DEK promotes cancer cell phenotypes by regulating transcription factors. We analyzed the interaction between DEK and the transcription factors to evaluate this hypothesis. We found that DEK binds to the basic regions within the basic leucine zipper (bZIP)‐ and basic helix–loop–helix leucine zipper (bHLH‐ZIP)‐ transcription factors. Interestingly, DEK enhanced the DNA‐binding capacity of two bZIP transcription factors, C/EBPα and ATF3, in vitro without being a component of the transcription factor‐DNA complex. We performed DEK knockdown in lung adenocarcinoma A549 cells and examined the global transcriptome changes to determine the biological significance of the interaction between DEK and transcription factors. We found that diverse genes regulating cell growth and amino acid metabolism, which may potentially be regulated by c‐Jun, a subunit of the bZIP transcription factor AP1, and c‐Myc, a bHLH‐ZIP transcription factor, were decreased by DEK knockdown. Consistent with these transcriptome changes, the cell growth, colony formation, and cell migration abilities of A549 cells were decreased by DEK knockdown. These results suggest that DEK promotes cancer cell malignancy by regulating the functions of the bZIP and bHLH‐ZIP transcription factors.
- 28 July 2021
- Published by Wiley in Genes to Cells
- Vol. 26 (10) , 830-837
SET‐NUP214 and MLL cooperatively regulate the promoter activity of the HoxA10 gene
SET‐Nup214 is a recurrent fusion gene that is mainly observed in T‐cell acute lymphoblastic leukemia (T‐ALL). Dysregulation of homeobox (Hox) genes is frequently observed in patients with leukemia. Consistent with this, HoxA genes are upregulated in the SET‐Nup214 + T‐ALL cell line and patients. Although SET‐Nup214 has been reported to be recruited to the promoter regions of HoxA genes, the detailed mechanisms of how SET‐Nup214 specifically binds to HoxA gene promoters and regulates HoxA gene expression are not known. In this study, we demonstrated that SET‐Nup214 interacts with MLL via the SET acidic region of SET‐Nup214. SET‐Nup214 and MLL cooperatively enhance the promoter activity of the HoxA10 gene. Neither the SET region alone nor the Nup214 region alone sufficiently enhanced the HoxA10 gene promoter. Our results indicated that the SET portion of the SET‐Nup214‐fusion protein is important for interactions with MLL and transcription enhancement of the HoxA10 gene. Thus, our study will contribute to the understanding of how SET‐Nup214 and MLL disturb the expression of HoxA10 gene in leukemia.
- 28 July 2021
- Published by Wiley in Genes to Cells
- Vol. 26 (10) , 830-837
SET‐NUP214 and MLL cooperatively regulate the promoter activity of the HoxA10 gene
SET‐Nup214 is a recurrent fusion gene that is mainly observed in T‐cell acute lymphoblastic leukemia (T‐ALL). Dysregulation of homeobox (Hox) genes is frequently observed in patients with leukemia. Consistent with this, HoxA genes are upregulated in the SET‐Nup214 + T‐ALL cell line and patients. Although SET‐Nup214 has been reported to be recruited to the promoter regions of HoxA genes, the detailed mechanisms of how SET‐Nup214 specifically binds to HoxA gene promoters and regulates HoxA gene expression are not known. In this study, we demonstrated that SET‐Nup214 interacts with MLL via the SET acidic region of SET‐Nup214. SET‐Nup214 and MLL cooperatively enhance the promoter activity of the HoxA10 gene. Neither the SET region alone nor the Nup214 region alone sufficiently enhanced the HoxA10 gene promoter. Our results indicated that the SET portion of the SET‐Nup214‐fusion protein is important for interactions with MLL and transcription enhancement of the HoxA10 gene. Thus, our study will contribute to the understanding of how SET‐Nup214 and MLL disturb the expression of HoxA10 gene in leukemia.
- 1 January 2016
- Published by American Psychological Association (APA)
Japanese Indecisiveness (Yujufudan) Scale
- 1 January 2016
- Published by American Psychological Association (APA)
Japanese Indecisiveness (Yujufudan) Scale
- 31 July 2015
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 5 (88) , 71709-71717
Antibacterial activities of polymeric poly(dl-lactide-co-glycolide) nanoparticles and Soluplus® micelles against Staphylococcus epidermidis biofilm and their characterization
Preparation method of polymeric micelles based on polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer (Soluplus®) have been successfully established as nanocarriers for a drug delivery system on a biofilm formed by Staphylococcus epidermidis. The biodegradable poly(DL-lactide-co-glycolide) (PLGA) nanoparticles were also prepared for comparison. To design effective nanocarriers against biofilm infections, we tested the four types of polymeric nanocarriers on the biofilm: unmodified PLGA, PLGA modified with chitosan (CS), unmodified Soluplus® micelles (Sol), and Sol modified with CS. The antibacterial activity of each nanocarrier against the biofilm was evaluated using field emission scanning electron microscopy (FE-SEM) with hydrophilic ionic liquid (IL) and confocal laser scanning microscopy. FE-SEM results revealed the exact morphology of carriers and bacterial cells at the nanoscale level by an optimized method using IL. The nanocarriers adhering to the biofilm were quantified using the phenol–sulfuric acid method. Antibacterial activity of nanocarriers was determined by minimum inhibitory concentration and minimum bactericidal concentration, and antibacterial assay using LIVE/DEAD BacLight bacterial viability kit. The highest antibacterial activity against the biofilm was demonstrated by a prepared Sol modified with CS. This nanocarrier would be useful for curing biofilm infections. In addition, visualization of the antibacterial activity at the nanoscale level could help in designing effective nanocarriers for target agents.
- 31 July 2015
- Published by Royal Society of Chemistry (RSC) in RSC Advances
- Vol. 5 (88) , 71709-71717
Antibacterial activities of polymeric poly(dl-lactide-co-glycolide) nanoparticles and Soluplus® micelles against Staphylococcus epidermidis biofilm and their characterization
Preparation method of polymeric micelles based on polyvinyl caprolactam–polyvinyl acetate–polyethylene glycol graft copolymer (Soluplus®) have been successfully established as nanocarriers for a drug delivery system on a biofilm formed by Staphylococcus epidermidis. The biodegradable poly(DL-lactide-co-glycolide) (PLGA) nanoparticles were also prepared for comparison. To design effective nanocarriers against biofilm infections, we tested the four types of polymeric nanocarriers on the biofilm: unmodified PLGA, PLGA modified with chitosan (CS), unmodified Soluplus® micelles (Sol), and Sol modified with CS. The antibacterial activity of each nanocarrier against the biofilm was evaluated using field emission scanning electron microscopy (FE-SEM) with hydrophilic ionic liquid (IL) and confocal laser scanning microscopy. FE-SEM results revealed the exact morphology of carriers and bacterial cells at the nanoscale level by an optimized method using IL. The nanocarriers adhering to the biofilm were quantified using the phenol–sulfuric acid method. Antibacterial activity of nanocarriers was determined by minimum inhibitory concentration and minimum bactericidal concentration, and antibacterial assay using LIVE/DEAD BacLight bacterial viability kit. The highest antibacterial activity against the biofilm was demonstrated by a prepared Sol modified with CS. This nanocarrier would be useful for curing biofilm infections. In addition, visualization of the antibacterial activity at the nanoscale level could help in designing effective nanocarriers for target agents.